Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men
An estimated 56,000 human immunodeficiency virus (HIV) infections occur each year in the United States. Men who have sex with men (MSM) account for 53% of the estimated incident infections, and surveillance data suggest that the annual number of new HIV infections among MSM has been rising since the...
Gespeichert in:
| Veröffentlicht in: | MMWR. Morbidity and mortality weekly report 2011-01, Vol.60 (3), p.65-68 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 68 |
|---|---|
| container_issue | 3 |
| container_start_page | 65 |
| container_title | MMWR. Morbidity and mortality weekly report |
| container_volume | 60 |
| creator | Smith, D.K Grant, R.M Weidle, P.J Lansky, A Mermin, J Fenton, K.A |
| description | An estimated 56,000 human immunodeficiency virus (HIV) infections occur each year in the United States. Men who have sex with men (MSM) account for 53% of the estimated incident infections, and surveillance data suggest that the annual number of new HIV infections among MSM has been rising since the mid-1990s. Strategies for reducing acquisition of HIV infection by MSM have included 1) expanded HIV testing so that infected persons can be treated and their risk for transmitting infection minimized; 2) individual, small-group, and community-level behavioral interventions to reduce risk behaviors; 3) promotion of condom use; 4) detection and treatment of sexually transmitted infections; and 5) mental health and substance abuse counseling when needed. On November 23, 2010, investigators for the Pre-Exposure Prophylaxis Initiative (iPrEX) study announced results from a multinational, randomized, double-blind, placebo-controlled, phase III clinical trial of daily oral antiretrovirals (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) to prevent acquisition of HIV infection among uninfected but exposed MSM. This report provides interim guidance to health-care providers based on the reported results of that trial, which indicated that TDF plus FTC taken orally once a day as preexposure prophylaxis (PrEP) is safe and partially effective in reducing HIV acquisition among MSM when provided with regular monitoring of HIV status and ongoing risk-reduction and PrEP medication adherence counseling. |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_reports_849023752</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A249136669</galeid><jstor_id>23320695</jstor_id><sourcerecordid>A249136669</sourcerecordid><originalsourceid>FETCH-LOGICAL-g309t-460a18e1a5e0bcd0a45311ebf8093b4b9c411978dc5a467132abfb367a4425aa3</originalsourceid><addsrcrecordid>eNpt0V1v0zAUBuAIgVjZ-AkgI6RxFWTHdhJzN03bWmkIJMbHXXSSnDSuUjvYztb9exw6BEO1L2y9fo4lHz9JFkwKmZY5-_E0WVAmVJoxJY-SF95v6Dw4fZ4cZSwraCH4ItmsTECnt-Rq0i2YBj-Qzw5xN1o_OYx7O_b3A-y0J511JPRzhrdograG2I4sV9_IynTY_A60IR_RkO-9JUu4RfIFd-ROh35OT5JnHQweXz6sx8nXy4ub82V6_elqdX52na45VSEVOQVWIgOJtG5aCkJyxrDuSqp4LWrVCMZUUbaNBJEXjGdQdzXPCxAikwD8OHmzv3d09ueEPlQOR-uCr0qhaMYLmUXz7j-z1b7BYQCDdpplyWPjOI_y7V6uYcBKm84GB82sq7NMKMbzPFdRpQfUGg06GKzBTsf4kX9_wMfZ4lY3BwtO_ynoEYbQeztMc9f9Y_j64WVTvcW2GuPngruv_nx5BK_2YOODdX_POc9oriT_BcOXrhc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>849023752</pqid></control><display><type>article</type><title>Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Smith, D.K ; Grant, R.M ; Weidle, P.J ; Lansky, A ; Mermin, J ; Fenton, K.A</creator><creatorcontrib>Smith, D.K ; Grant, R.M ; Weidle, P.J ; Lansky, A ; Mermin, J ; Fenton, K.A ; Centers for Disease Control and Prevention (CDC)</creatorcontrib><description>An estimated 56,000 human immunodeficiency virus (HIV) infections occur each year in the United States. Men who have sex with men (MSM) account for 53% of the estimated incident infections, and surveillance data suggest that the annual number of new HIV infections among MSM has been rising since the mid-1990s. Strategies for reducing acquisition of HIV infection by MSM have included 1) expanded HIV testing so that infected persons can be treated and their risk for transmitting infection minimized; 2) individual, small-group, and community-level behavioral interventions to reduce risk behaviors; 3) promotion of condom use; 4) detection and treatment of sexually transmitted infections; and 5) mental health and substance abuse counseling when needed. On November 23, 2010, investigators for the Pre-Exposure Prophylaxis Initiative (iPrEX) study announced results from a multinational, randomized, double-blind, placebo-controlled, phase III clinical trial of daily oral antiretrovirals (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) to prevent acquisition of HIV infection among uninfected but exposed MSM. This report provides interim guidance to health-care providers based on the reported results of that trial, which indicated that TDF plus FTC taken orally once a day as preexposure prophylaxis (PrEP) is safe and partially effective in reducing HIV acquisition among MSM when provided with regular monitoring of HIV status and ongoing risk-reduction and PrEP medication adherence counseling.</description><identifier>ISSN: 0149-2195</identifier><identifier>EISSN: 1545-861X</identifier><identifier>PMID: 21270743</identifier><language>eng</language><publisher>United States: Centers for Disease Control and Prevention</publisher><subject><![CDATA[Adenine - administration & dosage ; Adenine - analogs & derivatives ; Antiviral Agents - therapeutic use ; Clinical trials ; Condoms ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Disease prevention ; Disease transmission ; Double-Blind Method ; Drug Therapy, Combination ; Emtricitabine ; Experimentation ; Gays & lesbians ; Hepatitis B ; HIV ; HIV (Viruses) ; HIV infection ; HIV infections ; HIV Infections - prevention & control ; HIV testing ; Homosexuality, Male ; Human immunodeficiency virus ; Humans ; Infections ; Male ; Medical research ; Medication adherence ; Medications ; Medicine, Experimental ; Organophosphonates - administration & dosage ; Pills ; Prevention ; Sexually transmitted diseases ; Tenofovir ; Unsafe Sex]]></subject><ispartof>MMWR. Morbidity and mortality weekly report, 2011-01, Vol.60 (3), p.65-68</ispartof><rights>COPYRIGHT 2011 U.S. Government Printing Office</rights><rights>Copyright U.S. Center for Disease Control Jan 28, 2011</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/23320695$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/23320695$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,58015,58248</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21270743$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, D.K</creatorcontrib><creatorcontrib>Grant, R.M</creatorcontrib><creatorcontrib>Weidle, P.J</creatorcontrib><creatorcontrib>Lansky, A</creatorcontrib><creatorcontrib>Mermin, J</creatorcontrib><creatorcontrib>Fenton, K.A</creatorcontrib><creatorcontrib>Centers for Disease Control and Prevention (CDC)</creatorcontrib><title>Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men</title><title>MMWR. Morbidity and mortality weekly report</title><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><description>An estimated 56,000 human immunodeficiency virus (HIV) infections occur each year in the United States. Men who have sex with men (MSM) account for 53% of the estimated incident infections, and surveillance data suggest that the annual number of new HIV infections among MSM has been rising since the mid-1990s. Strategies for reducing acquisition of HIV infection by MSM have included 1) expanded HIV testing so that infected persons can be treated and their risk for transmitting infection minimized; 2) individual, small-group, and community-level behavioral interventions to reduce risk behaviors; 3) promotion of condom use; 4) detection and treatment of sexually transmitted infections; and 5) mental health and substance abuse counseling when needed. On November 23, 2010, investigators for the Pre-Exposure Prophylaxis Initiative (iPrEX) study announced results from a multinational, randomized, double-blind, placebo-controlled, phase III clinical trial of daily oral antiretrovirals (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) to prevent acquisition of HIV infection among uninfected but exposed MSM. This report provides interim guidance to health-care providers based on the reported results of that trial, which indicated that TDF plus FTC taken orally once a day as preexposure prophylaxis (PrEP) is safe and partially effective in reducing HIV acquisition among MSM when provided with regular monitoring of HIV status and ongoing risk-reduction and PrEP medication adherence counseling.</description><subject>Adenine - administration & dosage</subject><subject>Adenine - analogs & derivatives</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Clinical trials</subject><subject>Condoms</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Disease prevention</subject><subject>Disease transmission</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Emtricitabine</subject><subject>Experimentation</subject><subject>Gays & lesbians</subject><subject>Hepatitis B</subject><subject>HIV</subject><subject>HIV (Viruses)</subject><subject>HIV infection</subject><subject>HIV infections</subject><subject>HIV Infections - prevention & control</subject><subject>HIV testing</subject><subject>Homosexuality, Male</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Male</subject><subject>Medical research</subject><subject>Medication adherence</subject><subject>Medications</subject><subject>Medicine, Experimental</subject><subject>Organophosphonates - administration & dosage</subject><subject>Pills</subject><subject>Prevention</subject><subject>Sexually transmitted diseases</subject><subject>Tenofovir</subject><subject>Unsafe Sex</subject><issn>0149-2195</issn><issn>1545-861X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0V1v0zAUBuAIgVjZ-AkgI6RxFWTHdhJzN03bWmkIJMbHXXSSnDSuUjvYztb9exw6BEO1L2y9fo4lHz9JFkwKmZY5-_E0WVAmVJoxJY-SF95v6Dw4fZ4cZSwraCH4ItmsTECnt-Rq0i2YBj-Qzw5xN1o_OYx7O_b3A-y0J511JPRzhrdograG2I4sV9_IynTY_A60IR_RkO-9JUu4RfIFd-ROh35OT5JnHQweXz6sx8nXy4ub82V6_elqdX52na45VSEVOQVWIgOJtG5aCkJyxrDuSqp4LWrVCMZUUbaNBJEXjGdQdzXPCxAikwD8OHmzv3d09ueEPlQOR-uCr0qhaMYLmUXz7j-z1b7BYQCDdpplyWPjOI_y7V6uYcBKm84GB82sq7NMKMbzPFdRpQfUGg06GKzBTsf4kX9_wMfZ4lY3BwtO_ynoEYbQeztMc9f9Y_j64WVTvcW2GuPngruv_nx5BK_2YOODdX_POc9oriT_BcOXrhc</recordid><startdate>20110128</startdate><enddate>20110128</enddate><creator>Smith, D.K</creator><creator>Grant, R.M</creator><creator>Weidle, P.J</creator><creator>Lansky, A</creator><creator>Mermin, J</creator><creator>Fenton, K.A</creator><general>Centers for Disease Control and Prevention</general><general>U.S. Government Printing Office</general><general>U.S. Center for Disease Control</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>0-V</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>88F</scope><scope>88J</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M1Q</scope><scope>M2O</scope><scope>M2R</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20110128</creationdate><title>Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men</title><author>Smith, D.K ; Grant, R.M ; Weidle, P.J ; Lansky, A ; Mermin, J ; Fenton, K.A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g309t-460a18e1a5e0bcd0a45311ebf8093b4b9c411978dc5a467132abfb367a4425aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adenine - administration & dosage</topic><topic>Adenine - analogs & derivatives</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Clinical trials</topic><topic>Condoms</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Disease prevention</topic><topic>Disease transmission</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Emtricitabine</topic><topic>Experimentation</topic><topic>Gays & lesbians</topic><topic>Hepatitis B</topic><topic>HIV</topic><topic>HIV (Viruses)</topic><topic>HIV infection</topic><topic>HIV infections</topic><topic>HIV Infections - prevention & control</topic><topic>HIV testing</topic><topic>Homosexuality, Male</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Male</topic><topic>Medical research</topic><topic>Medication adherence</topic><topic>Medications</topic><topic>Medicine, Experimental</topic><topic>Organophosphonates - administration & dosage</topic><topic>Pills</topic><topic>Prevention</topic><topic>Sexually transmitted diseases</topic><topic>Tenofovir</topic><topic>Unsafe Sex</topic><toplevel>online_resources</toplevel><creatorcontrib>Smith, D.K</creatorcontrib><creatorcontrib>Grant, R.M</creatorcontrib><creatorcontrib>Weidle, P.J</creatorcontrib><creatorcontrib>Lansky, A</creatorcontrib><creatorcontrib>Mermin, J</creatorcontrib><creatorcontrib>Fenton, K.A</creatorcontrib><creatorcontrib>Centers for Disease Control and Prevention (CDC)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Military Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Military Database</collection><collection>Research Library</collection><collection>Social Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>MMWR. Morbidity and mortality weekly report</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, D.K</au><au>Grant, R.M</au><au>Weidle, P.J</au><au>Lansky, A</au><au>Mermin, J</au><au>Fenton, K.A</au><aucorp>Centers for Disease Control and Prevention (CDC)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men</atitle><jtitle>MMWR. Morbidity and mortality weekly report</jtitle><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><date>2011-01-28</date><risdate>2011</risdate><volume>60</volume><issue>3</issue><spage>65</spage><epage>68</epage><pages>65-68</pages><issn>0149-2195</issn><eissn>1545-861X</eissn><abstract>An estimated 56,000 human immunodeficiency virus (HIV) infections occur each year in the United States. Men who have sex with men (MSM) account for 53% of the estimated incident infections, and surveillance data suggest that the annual number of new HIV infections among MSM has been rising since the mid-1990s. Strategies for reducing acquisition of HIV infection by MSM have included 1) expanded HIV testing so that infected persons can be treated and their risk for transmitting infection minimized; 2) individual, small-group, and community-level behavioral interventions to reduce risk behaviors; 3) promotion of condom use; 4) detection and treatment of sexually transmitted infections; and 5) mental health and substance abuse counseling when needed. On November 23, 2010, investigators for the Pre-Exposure Prophylaxis Initiative (iPrEX) study announced results from a multinational, randomized, double-blind, placebo-controlled, phase III clinical trial of daily oral antiretrovirals (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) to prevent acquisition of HIV infection among uninfected but exposed MSM. This report provides interim guidance to health-care providers based on the reported results of that trial, which indicated that TDF plus FTC taken orally once a day as preexposure prophylaxis (PrEP) is safe and partially effective in reducing HIV acquisition among MSM when provided with regular monitoring of HIV status and ongoing risk-reduction and PrEP medication adherence counseling.</abstract><cop>United States</cop><pub>Centers for Disease Control and Prevention</pub><pmid>21270743</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2195 |
| ispartof | MMWR. Morbidity and mortality weekly report, 2011-01, Vol.60 (3), p.65-68 |
| issn | 0149-2195 1545-861X |
| language | eng |
| recordid | cdi_proquest_reports_849023752 |
| source | MEDLINE; JSTOR Archive Collection A-Z Listing; EZB-FREE-00999 freely available EZB journals |
| subjects | Adenine - administration & dosage Adenine - analogs & derivatives Antiviral Agents - therapeutic use Clinical trials Condoms Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease prevention Disease transmission Double-Blind Method Drug Therapy, Combination Emtricitabine Experimentation Gays & lesbians Hepatitis B HIV HIV (Viruses) HIV infection HIV infections HIV Infections - prevention & control HIV testing Homosexuality, Male Human immunodeficiency virus Humans Infections Male Medical research Medication adherence Medications Medicine, Experimental Organophosphonates - administration & dosage Pills Prevention Sexually transmitted diseases Tenofovir Unsafe Sex |
| title | Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T16%3A49%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interim%20Guidance:%20Preexposure%20Prophylaxis%20for%20the%20Prevention%20of%20HIV%20Infection%20in%20Men%20Who%20Have%20Sex%20with%20Men&rft.jtitle=MMWR.%20Morbidity%20and%20mortality%20weekly%20report&rft.au=Smith,%20D.K&rft.aucorp=Centers%20for%20Disease%20Control%20and%20Prevention%20(CDC)&rft.date=2011-01-28&rft.volume=60&rft.issue=3&rft.spage=65&rft.epage=68&rft.pages=65-68&rft.issn=0149-2195&rft.eissn=1545-861X&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA249136669%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=849023752&rft_id=info:pmid/21270743&rft_galeid=A249136669&rft_jstor_id=23320695&rfr_iscdi=true |